nless contra-indicated.
In NSTE-ACS patients planned to undergo PCI within the first 4 hours of diagnosis or in patients with acute myocardial infarction intended for primary PCI, Aggrastat should be administered utilizing an initial bolus of 25 microgram/kg given over a 3 minute period, followed by a continuous infusion at a rate of 0.15 microgram/kg/min for 12-24, and up to 48 hours. Aggrastat should be administered with unfractionated heparin (dosage as above) and oral antiplatelet therapy, including but not limited to ASA (see section 5.1), unless contra-indicated.
Elderly
No dosage adjustment is necessary for the elderly (see section 4.4).
Patients with severe kidney failure
In severe kidney failure (creatinine clearance <30 ml/min) the dosage of Aggrastat should be reduced by 50% (see sections 4.4 and 5.2).
Paediatric population
The safety and efficacy of Aggrastat in children aged < 18 years have not been established.
No data are available.
Table 1 is provided as a guide to dosage adjustment by weight.
Aggrastat Concentrate must be diluted to the same strength as Aggrastat Solution, as noted under Instructions for Use.
Table 1: Dosing Table
0.4 microgram/kg/min
Loading Dose Regimen
Most Patients
0.4 microgram/kg/min
Loading Dose Regimen
Severe Kidney Failure
25 microgram/kg
Dose Bolus Regimen
Most Patients
25 microgram/kg
Dose Bolus Regimen
Severe Kidney Failure
30 min Loading Infusion Rate (ml/hr)
Maintenance Infusion Rate (ml/hr)
30 min Loading Infusion Rate (ml/hr)
Maintenance Infusion Rate (ml/hr)
Bolus (ml)
Maintenance Infusion Rate (ml/hr)
Bolus (ml)
Maintenance Infusion Rate (ml/hr)
30-37
16
4
8
2
17
6
8
3
38-45
20
5
10
3
21
7
10
4
46-54
24
6
12
3
25
9
13
5
55-62
28
7
14
4
29
11
15
5
63-70
32
8
16
4
33
12
17
6
71-79
36
9
18
5
38
14
19
7
80-87
40
10
20
5
42
15
21
8
88-95
44
11
22
6
46
16
23
8
96-104
48
12
24
6
50
18
25
9
105-112
52
13
26
7
54
20
27
10
113-120
56
14
28
7
58
21
29
10
121-128
60
15
30
8
62
22
31
&nb
